Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early secukinumab versus standard care in newly diagnosed moderate to severe psoriatic arthritis
2018-004724-11Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of secukinumab in psoriatic arthritis (PsA) (2 arms), sponsored by Erasmus MC. Primary endpoint: ACR50 response at 6 months. Started Jul 2019; status: active.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2018-004724-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004724-11.